RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia gravis (MG) in Chinese patients, showing positive results. For the multicenter, randomized, open-label Phase II clinical study, the subjects were adult patients diagnosed with myasthenia gravis (MG), who had tested positive for acetylcholine receptor antibodies, and were receiving standardized medical therapy....